Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged ipr · clear
Written by Scott Raevsky and Mark Rubinshtein , Ph.D. The Patent Trial and Appeal Board issued concurrent final written decisions upholding the validity of all challenged claims of U.S. Patent No. 8,141,154 in Palo Alto Networks, Inc. v. Finjan. Inc.…
Written by Peter Heuser, Schwabe Williamson & Wyatt In Nidec v. Zhongshan , the panel reverses a determination of anticipation, noting that the Circuit’s Kennametal case does not stand for the proposition that anticipation can be found even when a…
Written by Daniel K. Yarbrough, Ph.D. and Kerry S. Taylor, Ph.D. Bevacizumab (Avastin®) is the subject of the widely watched “patent dance” dispute between Genentech and Amgen regarding Amgen’s proposed biosimilar. Hospira, however,…
Written by Damien Howard and Nathanael Luman, Ph.D. The Patent Trial and Appeal Board (“PTAB”) invoked its discretion under 35 U.S.C. § 325(d) to deny Toyota’s IPR petition against Adaptive Headlamp’s U.S. Patent No. 7,241,034…
Couple of weeks ago we reported that Zond ranked first among patent owners with 125 IPR challenges filed against 10 of its patents. This week we delved into the claim-level analysis of these IPR cases. A total of 371 unique claims had been challenged, and…
Written by Casey D. Donahoe, Ph.D. and Kerry S. Taylor, Ph.D. The Patent Trial and Appeal Board granted a rare request for rehearing of its earlier decision denying institution of an asserted anticipation ground in Asustek Computer, Inc. v. Avago…
Written by Neil G. Anderson and Benjamin Anger The Federal Circuit affirmed the PTAB’s final written decision holding that claims from Michael Meiresonne’s patent were obvious in Meiresonne v. Google, Inc., Case No. 16-1755 (Fed. Cir. Mar. 7,…
Written by Mark E. Davis and Kerry S. Taylor, Ph.D. The PTAB issued two final written decisions upholding The University of Pennsylvania’s claims to methods of treating high cholesterol based, in part, on commercial success and the meaning of a…
Last week, we released the top 10 patent owners whose patents had been challenged the most since the inception of Inter-Partes Review (IPR). Zond ranked first with a total of 125 IPR challenges filed against ten of its patents. This week, our Data Science…
Eli Lilly is not likely to think of the Circuit’s handling of its successful IPR as an “intimate ‎moment,” given that the Circuit reversed a finding of invalidity of all of the claims of a patent ‎directed against its Cialis ED…
The last few weeks, our Data Science Team analyzed the most active petitioners in Inter-Partes Review (IPR) cases. Now we have turned our attention towards the patent owners in IPR cases. Our analysis shows that since IPR’s inception in 2012 through…
Written by Kerry S. Taylor, Ph.D. and Nathanael Luman, Ph.D. The PTAB issued a Final Written Decision upholding Pozen’s ulcer reducing Vimovo® claims based on unexpected results in Coalition For Affordable Drugs VII LLC v. Pozen Inc.,…
